MEI Pharma (MEIP) and Kyowa Kirin Report Clinical Data on Zandelisib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
June 10, 2022 3:00 AM EDTZandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate
87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles
9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event
Primarily, Grade 3 AESIs to Date Occurred in Cycles 1-3.
SAN DIEGO & TOKYO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty... More
